share_log

Pfizer | 11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

Pfizer | 11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

輝瑞 | 11-K：員工持股年度報告
美股sec公告 ·  06/12 02:43
牛牛AI助理已提取核心訊息
Pfizer Inc. has filed its annual report on Form 11-K with the SEC for the fiscal year ended December 31, 2023. The report includes audited financial statements of the Pfizer Savings Plan, which is available to employees for stock purchase, savings, and similar plans. The independent audit, conducted by KPMG LLP, concluded that the financial statements present fairly the net assets available for plan benefits as of December 31, 2023, and the changes in net assets for the year in accordance with U.S. GAAP. The report details the Plan's investments, including Pfizer Inc. common stock, mutual funds, and other assets totaling approximately $19.7 billion, an increase from the previous year's $18 billion. The Plan experienced a net investment gain of over $2 billion for...Show More
Pfizer Inc. has filed its annual report on Form 11-K with the SEC for the fiscal year ended December 31, 2023. The report includes audited financial statements of the Pfizer Savings Plan, which is available to employees for stock purchase, savings, and similar plans. The independent audit, conducted by KPMG LLP, concluded that the financial statements present fairly the net assets available for plan benefits as of December 31, 2023, and the changes in net assets for the year in accordance with U.S. GAAP. The report details the Plan's investments, including Pfizer Inc. common stock, mutual funds, and other assets totaling approximately $19.7 billion, an increase from the previous year's $18 billion. The Plan experienced a net investment gain of over $2 billion for the year. The report also outlines the Plan's administrative details, contributions, rollovers, and participant-directed investments. Notably, the Plan underwent several mergers and transfers due to Pfizer's acquisitions, including Trillium Therapeutics, Arena Pharmaceuticals, ReViral Ltd., and Global Blood Therapeutics. The Plan is subject to ERISA and the Internal Revenue Code, with no current audits in progress for tax periods. The report also mentions subsequent events, including the acquisition of Seagen Inc. and the transfer of its 401(k) plan into the Pfizer Savings Plan.
輝瑞公司已向美國證券交易委員會提交了其截至2023年12月31日財年的Form 11-K年度報告。該報告包括輝瑞儲蓄計劃的審計財務報表，該計劃可供員工用於股票購買、儲蓄和類似計劃。由畢馬威會計師事務所進行的獨立審計認爲，財務報表按照美國通用會計準則作出的說明以及2023年12月31日計劃受益的淨資產變化公正地呈現。報告詳細介紹了計劃的投資情況，包括輝瑞公司普通股、所有基金類型和其他資產，總值約爲197億美元，較上一年的180億美元有所增長。該計劃今年實現了超過20億美元的淨投資收益。報告還概述了計劃的管理細節、貢獻、轉移和參與者指定的投資。值得注意的是，由於輝瑞的一些收購，包括Trillium...展開全部
輝瑞公司已向美國證券交易委員會提交了其截至2023年12月31日財年的Form 11-K年度報告。該報告包括輝瑞儲蓄計劃的審計財務報表，該計劃可供員工用於股票購買、儲蓄和類似計劃。由畢馬威會計師事務所進行的獨立審計認爲，財務報表按照美國通用會計準則作出的說明以及2023年12月31日計劃受益的淨資產變化公正地呈現。報告詳細介紹了計劃的投資情況，包括輝瑞公司普通股、所有基金類型和其他資產，總值約爲197億美元，較上一年的180億美元有所增長。該計劃今年實現了超過20億美元的淨投資收益。報告還概述了計劃的管理細節、貢獻、轉移和參與者指定的投資。值得注意的是，由於輝瑞的一些收購，包括Trillium Therapeutics、Arena Pharmaceuticals、ReViral Ltd.和全球血液療法，該計劃經歷了多次合併和轉移。該計劃受ERISA法和美國國內稅法的約束，目前沒有涉及稅期的審計。報告還提到了隨後發生的事件，包括收購Seagen Inc.和將其401(k)計劃轉入輝瑞儲蓄計劃。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。